Immunomodulatory News and Research

RSS

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

New research identifies potential treatment for primary effusion lymphoma

New research from the University of Southern California Norris Comprehensive Cancer Center has identified a potential treatment for a rare but previously incurable form of lymphoma that is observed primarily in patients with HIV/AIDS infection.

8 Jul 2015

Hepatic ALT flares linked to HBsAg clearance

Hepatic alanine aminotransferase flares are associated with rapid decline and greater annual reductions of hepatitis B surface antigen in patients with chronic hepatitis B virus infection who achieve HBsAg seroclearance, say Japanese researchers.

30 Jun 2015

New Christian Doppler Laboratory for Complement Research opens at MedUni Vienna

Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions.

26 Jun 2015

Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.

16 Jun 2015

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.

7 Jun 2015

$Elotuzumab boosts response in relapsed, refractory multiple myeloma$

Elotuzumab boosts response in relapsed, refractory multiple myeloma

Addition of the immunostimulatory antibody elotuzumab to the combination of lenalidomide and dexamethasone improves progression-free survival and the overall response rate in patients with relapsed or refractory multiple myeloma, research suggests.

4 Jun 2015

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

MorphoSys AG today published first safety and efficacy data on its proprietary drug candidate MOR202. The data are from a phase 1/2a study in 42 heavily pretreated patients with relapsed/refractory multiple myeloma.

2 Jun 2015

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis®

2 Jun 2015

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis®

2 Jun 2015

$Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma$

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

1 Jun 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.

30 May 2015

Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

Voices Against Brain Cancer, a national non-profit organization committed to finding a cure for brain cancer and brain tumors, and the Feinstein Institute for Medical Research in Long Island, will be hosting a Brain Tumor Biotech Summit on Friday, May 29th, 2015 at Lenox Hill Hospital's Einhorn Auditorium in Manhattan.

30 May 2015

Monoclonal antibody nivolumab improves survival rates of melanoma patients

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.

29 May 2015

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, announces that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform.

19 May 2015

Canada-US researchers to jointly study effectiveness of AIO treatment in patients with late stage cancer

Canadian and American health-care professionals will work together to study the effectiveness of advanced integrative oncology (AIO) treatment for patients with late stage cancer. AIO treatment includes elements of conventional and naturopathic medicine.

31 Mar 2015

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy.

30 Mar 2015

Co-infection reduces severity of East Coast fever, can help curb human malaria

When calves are infected by two parasite species at the same time, one parasite renders the other far less deadly, according to a new study published in the current journal of Science Advances.

24 Mar 2015

Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. Increased understanding of the microenvironmental interactions between malignant plasma cells and the bone marrow niche, and their role in disease progression and acquisition of therapy resistance, has helped the development of novel therapeutic drugs for use in combination with cytostatic therapy.

20 Jan 2015

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides.

14 Nov 2014

Immunomodulatory News and Research

Array Biopharma reports strong fourth quarter and full year 2015 financial results

New research identifies potential treatment for primary effusion lymphoma

Hepatic ALT flares linked to HBsAg clearance

New Christian Doppler Laboratory for Complement Research opens at MedUni Vienna

Novartis presents positive Phase III results of Farydak therapy at EHA

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Elotuzumab boosts response in relapsed, refractory multiple myeloma

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

Monoclonal antibody nivolumab improves survival rates of melanoma patients

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

Canada-US researchers to jointly study effectiveness of AIO treatment in patients with late stage cancer

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Co-infection reduces severity of East Coast fever, can help curb human malaria

Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News